99 related articles for article (PubMed ID: 25446431)
1. Characterization of the triazine, T4, a representative from a novel series of CaV2 inhibitors with strong state-dependence, poor use-dependence, and distinctively fast kinetics.
Swensen AM; Niforatos W; Lee CH; Jarvis MF; McGaraughty S
Eur J Pharmacol; 2014 Dec; 745():234-42. PubMed ID: 25446431
[TBL] [Abstract][Full Text] [Related]
2. Characterization of the substituted N-triazole oxindole TROX-1, a small-molecule, state-dependent inhibitor of Ca(V)2 calcium channels.
Swensen AM; Herrington J; Bugianesi RM; Dai G; Haedo RJ; Ratliff KS; Smith MM; Warren VA; Arneric SP; Eduljee C; Parker D; Snutch TP; Hoyt SB; London C; Duffy JL; Kaczorowski GJ; McManus OB
Mol Pharmacol; 2012 Mar; 81(3):488-97. PubMed ID: 22188924
[TBL] [Abstract][Full Text] [Related]
3. An automated electrophysiological assay for differentiating Ca(v)2.2 inhibitors based on state dependence and kinetics.
Swensen AM; Niforatos W; Vortherms TA; Perner RJ; Li T; Schrimpf MR; Scott VE; Lee L; Jarvis MF; McGaraughty S
Assay Drug Dev Technol; 2012 Dec; 10(6):542-50. PubMed ID: 22428804
[TBL] [Abstract][Full Text] [Related]
4. A high-throughput assay for evaluating state dependence and subtype selectivity of Cav2 calcium channel inhibitors.
Dai G; Haedo RJ; Warren VA; Ratliff KS; Bugianesi RM; Rush A; Williams ME; Herrington J; Smith MM; McManus OB; Swensen AM
Assay Drug Dev Technol; 2008 Apr; 6(2):195-212. PubMed ID: 18471074
[TBL] [Abstract][Full Text] [Related]
5. Analgesic effects of a substituted N-triazole oxindole (TROX-1), a state-dependent, voltage-gated calcium channel 2 blocker.
Abbadie C; McManus OB; Sun SY; Bugianesi RM; Dai G; Haedo RJ; Herrington JB; Kaczorowski GJ; Smith MM; Swensen AM; Warren VA; Williams B; Arneric SP; Eduljee C; Snutch TP; Tringham EW; Jochnowitz N; Liang A; Euan MacIntyre D; McGowan E; Mistry S; White VV; Hoyt SB; London C; Lyons KA; Bunting PB; Volksdorf S; Duffy JL
J Pharmacol Exp Ther; 2010 Aug; 334(2):545-55. PubMed ID: 20439438
[TBL] [Abstract][Full Text] [Related]
6. Mechanism of direct Cav2.2 channel block by the κ-opioid receptor agonist U50488H.
Berecki G; Motin L; Adams DJ
Neuropharmacology; 2016 Oct; 109():49-58. PubMed ID: 27245500
[TBL] [Abstract][Full Text] [Related]
7. "Slow" Voltage-Dependent Inactivation of CaV2.2 Calcium Channels Is Modulated by the PKC Activator Phorbol 12-Myristate 13-Acetate (PMA).
Zhu L; McDavid S; Currie KP
PLoS One; 2015; 10(7):e0134117. PubMed ID: 26222492
[TBL] [Abstract][Full Text] [Related]
8. Conserved biophysical features of the Ca
Gauberg J; Abdallah S; Elkhatib W; Harracksingh AN; Piekut T; Stanley EF; Senatore A
J Biol Chem; 2020 Dec; 295(52):18553-18578. PubMed ID: 33097592
[TBL] [Abstract][Full Text] [Related]
9. omega-conotoxin GVIA alters gating charge movement of N-type (CaV2.2) calcium channels.
Yarotskyy V; Elmslie KS
J Neurophysiol; 2009 Jan; 101(1):332-40. PubMed ID: 18971294
[TBL] [Abstract][Full Text] [Related]
10. Kinetics and Gbetagamma modulation of Ca(v)2.2 channels with different auxiliary beta subunits.
Meir A; Dolphin AC
Pflugers Arch; 2002 May; 444(1-2):263-75. PubMed ID: 11976940
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological characterization of recombinant N-type calcium channel (Cav2.2) mediated calcium mobilization using FLIPR.
Benjamin ER; Pruthi F; Olanrewaju S; Shan S; Hanway D; Liu X; Cerne R; Lavery D; Valenzano KJ; Woodward RM; Ilyin VI
Biochem Pharmacol; 2006 Sep; 72(6):770-82. PubMed ID: 16844100
[TBL] [Abstract][Full Text] [Related]
12. Neurokinin 1 receptors trigger overlapping stimulation and inhibition of CaV2.3 (R-type) calcium channels.
Meza U; Thapliyal A; Bannister RA; Adams BA
Mol Pharmacol; 2007 Jan; 71(1):284-93. PubMed ID: 17050807
[TBL] [Abstract][Full Text] [Related]
13. ZC88, a novel N-type calcium channel blocker from 4-amino-piperidine derivatives state-dependent inhibits Cav2.2 calcium channels.
Zhang S; Yang L; Zhang K; Liu X; Dai W; Zhang C; Yong Z; Li J; Zheng J
Brain Res; 2015 Apr; 1605():12-21. PubMed ID: 25681549
[TBL] [Abstract][Full Text] [Related]
14. An integrated multiassay approach to the discovery of small-molecule N-type voltage-gated calcium channel antagonists.
Finley MF; Lubin ML; Neeper MP; Beck E; Liu Y; Flores CM; Qin N
Assay Drug Dev Technol; 2010 Dec; 8(6):685-94. PubMed ID: 21050074
[TBL] [Abstract][Full Text] [Related]
15. Novel mechanism of voltage-gated N-type (Cav2.2) calcium channel inhibition revealed through α-conotoxin Vc1.1 activation of the GABA(B) receptor.
Huynh TG; Cuny H; Slesinger PA; Adams DJ
Mol Pharmacol; 2015 Feb; 87(2):240-50. PubMed ID: 25425625
[TBL] [Abstract][Full Text] [Related]
16. Fast Inactivation of Ca
Reyes-Vaca A; de la Cruz L; Garduño J; Arenas I; Garcia DE
J Mol Neurosci; 2017 Dec; 63(3-4):377-384. PubMed ID: 29063444
[TBL] [Abstract][Full Text] [Related]
17. Overexpressed Ca(v)beta3 inhibits N-type (Cav2.2) calcium channel currents through a hyperpolarizing shift of ultra-slow and closed-state inactivation.
Yasuda T; Lewis RJ; Adams DJ
J Gen Physiol; 2004 Apr; 123(4):401-16. PubMed ID: 15024042
[TBL] [Abstract][Full Text] [Related]
18. Discovery and mode of action of a novel analgesic β-toxin from the African spider Ceratogyrus darlingi.
Sousa SR; Wingerd JS; Brust A; Bladen C; Ragnarsson L; Herzig V; Deuis JR; Dutertre S; Vetter I; Zamponi GW; King GF; Alewood PF; Lewis RJ
PLoS One; 2017; 12(9):e0182848. PubMed ID: 28880874
[TBL] [Abstract][Full Text] [Related]
19. Closed-state inactivation and pore-blocker modulation mechanisms of human Ca
Dong Y; Gao Y; Xu S; Wang Y; Yu Z; Li Y; Li B; Yuan T; Yang B; Zhang XC; Jiang D; Huang Z; Zhao Y
Cell Rep; 2021 Nov; 37(5):109931. PubMed ID: 34731621
[TBL] [Abstract][Full Text] [Related]
20. Altered synaptic transmission at olfactory and vomeronasal nerve terminals in mice lacking N-type calcium channel Cav2.2.
Weiss J; Pyrski M; Weissgerber P; Zufall F
Eur J Neurosci; 2014 Nov; 40(10):3422-35. PubMed ID: 25195871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
